Vaxxinity Starts Dosing In Phase 1 Migraine Vaccine Trial

Vaxxinity Inc VAXX announced that the first subjects had been dosed in the Phase 1 clinical trial of UB-313, a vaccine targeting calcitonin gene-related peptide (CGRP), for the preventive treatment of migraine.
The Phase 1 randomized, placebo-controlled, double-blind, multidose trial will enroll approximately 40 healthy volunteers in Belgium.
The trial's objectives are to evaluate safety, tolerability, and immunogenicity. Serum anti-CGRP antibody titers will measure immunogenicity. Pharmacodynamics of the immune response will be measured by the inhibition of the capsaicin-induced increase in dermal blood flow, an established model of target engagement in migraine.
Price Action: VAXX shares are trading 2.09% higher at $2.20 on the last check Tuesday.